US Patent
US11707466 — Immediate release multilayer tablet
Formulation · Assigned to Alkermes Pharma Ireland Ltd · Expires 2041-11-12 · 15y remaining
Vulnerability score
50/100
Moderate — design-around opportunities exist
What this patent protects
This patent protects an immediate release multilayer tablet for orally delivering olanzapine and samidorphan.
USPTO Abstract
Described herein, in part, are tablets, such as immediate release multi-layer or bilayer tablets for orally delivering olanzapine and samidorphan, methods of using said tablets in the treatment of disorders described herein, and kits comprising said tablets.
Drugs covered by this patent
- Zyprexa (olanzapine) · Eli Lilly
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.